James S Blachly Gerard Lozanski David M Lucas Michael R Grever Kari Kendra Leslie A Andritsos
10.6004/jnccn.2015.0004
J Natl Compr Canc Netw
2015 Jan;13(1):9-13; quiz 13.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/25583765/
Antineoplastic Agents / therapeutic use Imidazoles / therapeutic use Leukemia, Hairy Cell / drug therapy Melanoma / drug therapy Neoplasms, Second Primary Oximes / therapeutic use Protein Kinase Inhibitors / therapeutic use
Antineoplastic Agents / therapeutic use Imidazoles / therapeutic use Leukemia, Hairy Cell / drug therapy Melanoma / drug therapy Neoplasms, Second Primary Oximes / therapeutic use Protein Kinase Inhibitors / therapeutic use Case Reports Aged Antineoplastic Agents / pharmacology Humans Imidazoles / pharmacology Leukemia, Hairy Cell / diagnosis Male Melanoma / diagnosis Mutation Oximes / pharmacology Positron-Emission Tomography Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins B-raf / antagonists & inhibitors Proto-Oncogene Proteins B-raf / genetics Tomography, X-Ray Computed Treatment Outcome Antineoplastic Agents Imidazoles Oximes Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf dabrafenib
PMC7250239
25583765
Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib
2015